Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 28, 2003. The report details specific corporate actions regarding share re-purchases and changes in directors' interests in ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to a specific share transaction:
- Share Re-purchase Price: 1214.97p per share.
- Shares Purchased: 800,000 ordinary shares.
Material Changes
The primary material change reported is the reduction of the company's share capital through a buyback program authorized by shareholders at the Annual General Meeting on May 19, 2003. Additionally, there were minor changes in directors' interests due to the transfer of shares from the GlaxoSmithKline Employee Trust to participants in long-term and mid-term incentive plans.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. The document is strictly a notification of the share cancellation and trustee transactions.
Key Facts for Investor Verification
- Verify the total number of shares remaining in the buyback authorization following the purchase of 800,000 shares.
- Confirm the total cost of the re-purchase (800,000 shares at 1214.97p).
- Review the impact of the 6,569 shares transferred from the GSK Trust to incentive plan participants on the total share count.